Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Sells $16,710.96 in Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube sold 1,372 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $16,710.96. Following the transaction, the chief accounting officer now owns 45,640 shares in the company, valued at $555,895.20. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Intellia Therapeutics Price Performance

Shares of NTLA stock opened at $12.02 on Friday. Intellia Therapeutics, Inc. has a one year low of $11.34 and a one year high of $34.87. The company has a market cap of $1.22 billion, a P/E ratio of -2.21 and a beta of 1.83. The firm has a 50-day moving average of $13.87 and a 200-day moving average of $19.10.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $8.28 million. During the same quarter last year, the business posted ($1.38) EPS. The company’s quarterly revenue was down 24.1% on a year-over-year basis. As a group, research analysts expect that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NTLA has been the topic of several research analyst reports. Citigroup cut their target price on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Barclays cut their price objective on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Wells Fargo & Company decreased their target price on Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating for the company in a research report on Monday, November 18th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $54.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $54.94.

Institutional Trading of Intellia Therapeutics

Hedge funds have recently bought and sold shares of the business. EverSource Wealth Advisors LLC grew its stake in Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after purchasing an additional 1,550 shares during the period. Eastern Bank bought a new position in Intellia Therapeutics during the third quarter valued at about $41,000. Values First Advisors Inc. bought a new position in Intellia Therapeutics during the third quarter valued at about $54,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Intellia Therapeutics by 27.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after buying an additional 794 shares during the last quarter. Finally, KBC Group NV raised its position in Intellia Therapeutics by 37.3% in the third quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after acquiring an additional 1,020 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.